Tamoxifen for women at high risk of breast cancer

Safia A Nazarali, Steven A Narod Women's College Research Institute, Women's College Hospital, and The University of Toronto, Toronto, Ontario, Canada Abstract: Tamoxifen has been used as a treatment for women who have been diagnosed with breast cancer for roughly four decades and...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nazarali SA, Narod SA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/4f6dcb6d642a44e9ab0b890e2ff41d2a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4f6dcb6d642a44e9ab0b890e2ff41d2a
record_format	dspace
spelling	oai:doaj.org-article:4f6dcb6d642a44e9ab0b890e2ff41d2a2021-12-02T08:40:19ZTamoxifen for women at high risk of breast cancer1179-1314https://doaj.org/article/4f6dcb6d642a44e9ab0b890e2ff41d2a2014-02-01T00:00:00Zhttp://www.dovepress.com/tamoxifen-for-women-at-high-risk-of-breast-cancer-a15849https://doaj.org/toc/1179-1314 Safia A Nazarali, Steven A Narod Women's College Research Institute, Women's College Hospital, and The University of Toronto, Toronto, Ontario, Canada Abstract: Tamoxifen has been used as a treatment for women who have been diagnosed with breast cancer for roughly four decades and has been approved as chemoprevention for over ten years. Although tamoxifen has been proven to be beneficial in preventing breast cancer in high-risk women, its use has not been widely embraced. To some extent, this is due to several of its side effects, including an increased risk of endometrial cancer and pulmonary embolism, but these serious side effects are rare. The risks and benefits of tamoxifen chemoprevention should be considered for each patient. Keywords: tamoxifen, breast cancer, women, chemopreventionNazarali SANarod SADove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2014, Iss default, Pp 29-36 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Nazarali SA Narod SA Tamoxifen for women at high risk of breast cancer
description	Safia A Nazarali, Steven A Narod Women's College Research Institute, Women's College Hospital, and The University of Toronto, Toronto, Ontario, Canada Abstract: Tamoxifen has been used as a treatment for women who have been diagnosed with breast cancer for roughly four decades and has been approved as chemoprevention for over ten years. Although tamoxifen has been proven to be beneficial in preventing breast cancer in high-risk women, its use has not been widely embraced. To some extent, this is due to several of its side effects, including an increased risk of endometrial cancer and pulmonary embolism, but these serious side effects are rare. The risks and benefits of tamoxifen chemoprevention should be considered for each patient. Keywords: tamoxifen, breast cancer, women, chemoprevention
format	article
author	Nazarali SA Narod SA
author_facet	Nazarali SA Narod SA
author_sort	Nazarali SA
title	Tamoxifen for women at high risk of breast cancer
title_short	Tamoxifen for women at high risk of breast cancer
title_full	Tamoxifen for women at high risk of breast cancer
title_fullStr	Tamoxifen for women at high risk of breast cancer
title_full_unstemmed	Tamoxifen for women at high risk of breast cancer
title_sort	tamoxifen for women at high risk of breast cancer
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/4f6dcb6d642a44e9ab0b890e2ff41d2a
work_keys_str_mv	AT nazaralisa tamoxifenforwomenathighriskofbreastcancer AT narodsa tamoxifenforwomenathighriskofbreastcancer
_version_	1718398416121233408

Tamoxifen for women at high risk of breast cancer

Ejemplares similares